Candesartan is one of the" youngest", but it is a well-studied representative of a
pharmacological group of sartans; it has a strong long-term antihypertensive effect, can …

Angiotensin II Receptor type 1 antagonists have been widely used in treatment of diseases
like hypertension, heart failure, myocardial infarction and diabetic nephropathy. Their …

Aim. To present a scientific review of angiotensin II (AT II) receptor blockers (sartans) clinical
pharmacology, in particular pharmacologic and clinical characteristics of candesartan …

Background Drugs that inhibit the renin–angiotensin–aldosterone system benefit patients at
risk for or with existing cardiovascular disease. However, evidence for this effect in Asian …

Valsartan (Diovan®) is a widely use angiotensin receptor blocker that prevents angiotensin
II from binding to the subtype 1 receptor. Stimulation of the subtype 1 receptor is believed to …

Background Based on the PARADIGM-HF study trial, sacubitril/valsartan (SV) was approved
by NICE in April 2016 (TA388) for patients with symptomatic heart failure. SV is …

Objective This study was designed mainly to establish the rates of response to valsartan 80
mg once daily (qd) and to valsartan 160 mg qd given to non-responders to 80 mg qd, as well …

Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension Page
1 ......................................................................................................... Advantages of sacubitril/valsartan …

Valsartan is a potent, highly selective angiotensin II receptor blocker used to treat
hypertension. This study examines the antihypertensive efficacy of valsartan in women and …